Ac-SDKP vs TB4-Frag
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Ac-SDKP or TB4-Frag?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Ac-SDKP and TB4-Frag?
Ac-SDKP is a well-characterized endogenous anti-fibrotic tetrapeptide with defined biological roles; TB4-Frag is a commercial product with unclear pharmacological advantage and an extremely short half-life that raises practical delivery questions.
Evidence Comparison
Ac-SDKP: dozens of peer-reviewed studies from multiple independent groups characterizing anti-fibrotic effects. TB4-Frag: commercially marketed thymosin beta-4 fragment with a reported 4.5-minute half-life and minimal peer-reviewed evidence. Ac-SDKP is the substantially stronger choice on evidence.
Evidence Context Favoring Ac-SDKP
Any anti-fibrotic or thymosin beta-4 fragment research - Ac-SDKP has the published evidence base.
Evidence Context Favoring TB4-Frag
There is no evidence-based scenario where TB4-Frag would be preferred over Ac-SDKP given the current literature.
Side-by-Side Snapshot
| Evidence grade | Ac-SDKP: Level D TB4-Frag: Level D |
|---|---|
| Research status | Ac-SDKP: Preclinical TB4-Frag: Preclinical |
| Primary category | Ac-SDKP: Healing & Recovery TB4-Frag: Healing & Recovery |
| Cited studies | Ac-SDKP: 3 TB4-Frag: 2 |